Supplementary Figure 1: Glucose and C-peptide response on MMTT from baseline to 26 wks

Imatinib, mean & 95% CI

Placebo, mean & 95% Cl



# Supplementary Figure 2: Circulating INS DNA over time





Plots are median and inter-quartile range

#### Supplementary Figure 2: Circulating *INS* DNA over time (cont.)



Supplementary Figure 2: Circulating *INS* DNA over time (cont.)





Plots are median and inter-quartile range

# Supplement Figure 3A: Autoantibody titers over time



### Supplement Figure 3B: Autoantibody titers over time



## Supplement Figure 3C: Autoantibody titers over time



## Supplement Figure 3D: Autoantibody titers over time



Supplementary Figure 4: Immune cell subsets over time

Imatinib 🔶 Placebo



Supplementary Figure 4: Immune cell subsets over time (cont)



Imatinib
Placebo

Supplementary Figure 4: Immune cell subsets over time (cont.)





#### Supplementary Figure 5: Highly metabolically active rare cell subsets over time



Imatinib + Placebo

#### Supplementary Figure 5: Highly metabolically active rare cell subsets over time (cont.)



◆ Imatinib ◆ Placebo

Supplementary Figure 6: Potentially protective immune cell subset populations in the upper versus lower quartile of C-peptide AUC responders in the imatinib group over time



Time on study (months)

- Tx-Lower Quartile - Tx-Upper Quartile

Supplementary Figure 6: Potentially protective immune cell subset populations in the upper versus lower quartile of C-peptide AUC responders in the imatinib group over time (cont.)



Tx-Lower Quartile Tx-Upper Quartile

Supplementary Figure 6: Potentially protective immune cell subset populations in the upper versus lower quartile of C-peptide AUC responders in the imatinib group over time (cont.)

